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Abstract
Background: Maternal mood disorders and their treatment during pregnancy may have effects on the offspring
epigenome. We aim to evaluate associations of maternal prenatal antidepressant use, anxiety, and depression with
cord blood DNA methylation across the genome at birth and test for persistence of associations in early and mid-
childhood blood DNA.
Methods: A discovery phase was conducted in Project Viva, a prospective pre-birth cohort study with external replication
in an independent cohort, the Generation R Study. In Project Viva, pregnant women were recruited between 1999 and
2002 in Eastern Massachusetts, USA. In the Generation R Study, pregnant women were recruited between 2002 and 2006
in Rotterdam, the Netherlands. In Project Viva, 479 infants had data on maternal antidepressant use, anxiety, depression,
and cord blood DNA methylation, 120 children had DNA methylation measured in early childhood (~ 3 years), and 460 in
mid-childhood (~ 7 years). In the Generation R Study, 999 infants had data on maternal antidepressants and cord blood
DNA methylation. The prenatal antidepressant prescription was obtained from medical records. At-mid pregnancy,
symptoms of anxiety and depression were assessed with the Pregnancy-Related Anxiety Scale and the Edinburgh
Postnatal Depression Scale in Project Viva and with the Brief Symptom Inventory in the Generation R Study. Genome-
wide DNA methylation was measured using the Infinium HumanMethylation450 BeadChip in both cohorts.
Results: In Project Viva, 2.9% (14/479) pregnant women were prescribed antidepressants, 9.0% (40/445) experienced high
pregnancy-related anxiety, and 8.2% (33/402) reported symptoms consistent with depression. Newborns exposed to
antidepressants in pregnancy had 7.2% lower DNA methylation (95% CI, − 10.4, − 4.1; P = 1.03 × 10−8) at cg22159528
located in the gene body of ZNF575, and this association replicated in the Generation R Study (β = − 2.5%; 95% CI − 4.2,
− 0.7; P = 0.006). In Project Viva, the association persisted in early (β = − 6.2%; 95% CI − 10.7, − 1.6) but not mid-
childhood. We observed cohort-specific associations for maternal anxiety and depression in Project Viva that did not
replicate.
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Conclusions: The ZNF575 gene is involved in transcriptional regulation but specific functions are largely unknown.
Given the widespread use of antidepressants in pregnancy, as well as the effects of exposure to anxiety and
depression, implications of potential fetal epigenetic programming by these risk factors and their impacts on
development merit further investigation.
Keywords: Maternal depression, Maternal anxiety, Antidepressants, DNA methylation, Fetal programming
Background
Anxiety and depression are common during pregnancy,
affecting up to 8% and 12% of pregnant women, respect-
ively [1–3]. Prenatal anxiety and depression are associated
with poor perinatal outcomes including suboptimal fetal
growth [4, 5] and preterm birth [6]. While generally
thought to be safe, medications to treat mood disorders in
pregnancy have been associated with risks of adverse
long-term consequences for children including impaired
neuromotor development [7] as well as behavioral and
emotional problems [8–11].
Antidepressants such as selective serotonin reuptake
inhibitors (SSRIs) are used to reduce symptoms of
anxiety and depression in approximately 8% of US
pregnant women [12]. Two recent reviews of the
literature found that fetuses exposed to antidepres-
sants such as SSRIs may have abnormal motor and
heart rate activity during fetal development [13, 14].
It is well established that early-life environments may
influence fetal and later child development [15].
Epigenetic processes during fetal development are one
pathway by which environmental factors may affect
phenotype later in life [16]. Whether antidepressants
or the underlying psychopathology in pregnancy
affects fetal programming through epigenetic pro-
cesses such as DNA methylation remains unknown.
Epigenome-wide association studies (EWAS) can be a
powerful tool to discover biomarkers of disease and to
understand biologic processes [17]. Using an epigenome-
wide approach, we aimed to identify differences in DNA
methylation in neonates associated with prenatal maternal
antidepressant use, anxiety, and depression. We hypothe-
sized that prenatal maternal exposure to antidepressants,
anxiety, and depression would lead to differences in DNA
methylation in cord blood that would persist into
childhood.
Results
Overall, in Project Viva, 2.9% (14/479) of women were
prescribed antidepressants during pregnancy, 9.0% (40/445)
experienced high pregnancy-related anxiety, and 8.2%
(33/402) reported symptoms consistent with depression in
pregnancy. In the Generation R Study, there were 999
mother-infant pairs eligible for analyses, 1.4% (14/999)
were prescribed antidepressants, 5.8% (56/969)
experienced high anxiety, and 3.2% (31/969) reported
symptoms consistent with clinical depression in preg-
nancy. Demographic characteristics of participants in both
cohorts are presented in Table 1.
In Project Viva, exposure to antidepressants was
associated with DNA methylation differences at 130 CpG
sites that passed FDR < 0.05, among which 16 sites also
passed Bonferroni significance (P < 1.34 × 10−7) in models
adjusted for maternal, parity, self-reported race, smoking
during pregnancy, body mass index (BMI), mode of
delivery, education and infant sex, gestational age at birth,
and nucleated cell-type proportions (Table 2). In replica-
tion analyses in the Generation R Study, among
Bonferroni significant sites discovered in Project Viva, we
confirmed that DNA methylation of one of these sites,
cg22159528, was significantly lower among infants whose
mothers were prescribed antidepressants during preg-
nancy. This CpG site is located in the body of the Zinc
Finger Protein 575 gene (ZNF575) on chromosome 19
and annotated to a CpG island. Specifically, in Project
Viva, we observed that infants born to mothers prescribed
antidepressant in pregnancy had 7.2% lower DNA methy-
lation (95% CI − 10.4, − 4.1; P = 1 × 10−8) at this site and in
the Generation R Study, exposed infants had 2.5% lower
DNA methylation (95% CI − 4.2, − 0.7; P = 0.006) at the
same site in adjusted models. In the discovery cohort, we
also observed an additional four CpG sites (cg01080902,
cg04798919, cg10571104, and cg17970176) near
cg22159528 in the ZNF575 gene that were nominally as-
sociated with antidepressant use (P < 0.05) in the replica-
tion cohort but did not reach a Bonferroni adjusted (0.05/
16) levels of significance (Fig. 1). One other CpG site in
the replication cohort (cg00367463; BEST4 gene) passed
the P < 0.05 criteria for replication but its effect estimate
was in the opposite direction.
In Project Viva, we observed 13 individual CpG sites dif-
ferentially methylated relative to high maternal
pregnancy-related anxiety and three individual sites
associated with prenatal maternal depression (FDR < 0.05)
but these associations were not robust to external
replication in the Generation R Study (Additional file 1:
Table S1). For single CpG analyses, the genomic inflation
factor (λ) was 0.87 for prenatal antidepressants, 1.17 for
high anxiety, and 0.94 for depression indicating a
reasonable fit (Additional file 2: Figure S1). As a secondary
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approach, we conducted regional analyses using DMRcate:
we did not find any differentially methylated regions rela-
tive to prenatal antidepressant prescription, anxiety, or de-
pression in the discovery cohort.
We evaluated the persistence of the observed association
at cg22159528 in the ZNF575 gene for antidepressants and
DNA methylation in Project Viva, in blood collected in
early and mid-childhood. In adjusted models, prenatally
exposed children (n = 4 out of 120) had 6.2% lower DNA
methylation (95% CI − 10.7 to − 1.6; P = 6.70 × 10−3) com-
pared to non-exposed children in early childhood. This
association was in the same direction but attenuated and
non-significant in mid-childhood (β = − 3.7, 95% CI − 8.8 to
1.4; P = 0.16) (n = 12 exposed out of 460). Unadjusted dif-
ferences in DNA methylation were similar to adjusted dif-
ferences for exposed and unexposed infants at birth, early,
and mid-childhood (Fig. 2).
To evaluate the potential neurological implications
of our findings, we tested correlations between blood
and brain DNA methylation using external reference
data. DNA methylation at cg22159528 in the
ZNF575 gene from over 70 adults showed positive
correlations between blood and brain tissue of the
prefrontal cortex (r = 0.54, P = 6.45 × 10−7), entorhinal
cortex (r = 0.41, P = 2.33 × 10−4), superior temporal
gyrus (r = 0.49, P = 7.87 × 10−8) but not the cerebel-
lum (r = − 0.01, P = 0.97) (Fig. 3). These results must
be interpreted with caution given that reference
blood and brain samples were collected from adults
and might not accurately reflect variation in cord
blood or early childhood blood samples with brain
DNA methylation.
Discussion
Using an agnostic epigenome-wide approach, we
observed differences in DNA methylation across mul-
tiple CpG sites for infants prenatally exposed to
maternal antidepressants and replicated this observation
at one CpG site. While 13 CpG sites were associated
with high maternal prenatal anxiety and three with pre-
natal maternal depression in Project Viva, we did not
confirm these associations in the Generation R Study. In
both Project Viva and Generation R Study, antidepres-
sant prescription during pregnancy was associated with
lower DNA methylation at a CpG site located within the
ZNF575 gene body. Exposure to antidepressants during
pregnancy was also associated with lower DNA methyla-
tion at this site in early childhood blood with a similar
Table 1 Characteristics of the discovery cohort, Project Viva, and the independent replication cohort, Generation R Study
Characteristics Discovery cohort Project Viva N = 479 Replication cohort Generation R Study N = 999
Maternal Mean (SD) or n (%)
Age, years 32.1 (5.4) 32.2 (4.3)
Pre-pregnancy BMI, kg/m2 24.7 (5.2) 23.4 (3.9)
Antidepressant use 14 (2.9%) 14 (1.4%)
High anxiety 40 (9.0%)a 56 (5.8%)b
Depression mid-pregnancy 33 (8.2%)a 31 (3.2%)b
Race/ethnicity
Non-Hispanic White 341 (71.2%) Dutch 931 (93.2%)
Non-Hispanic Black 56 (11.7%) Non-Dutch Western 63 (6.3%)
Hispanic 37 (7.7%) Non-western 5 (0.5%)
Other 45 (9.4%) –
College graduate or more education 317 (66.2%) 669 (67.0%)
Smoking status
Never 327 (68.3%) Never during pregnancy 772 (77.3%)
Former 100 (20.9%) Quit when pregnancy was known 93 (9.3%)
During pregnancy 52 (10.9%) Continued during pregnancy 134 (13.4%)
Perinatal/infant Mean (SD) or n (%)
Cesarean delivery 79 (16.5%) 103 (10.3%)
Gestational age at delivery, weeks 39.8 (1.4) 40.2 (1.4)
Birth weight-for-gestational age, z-score 0.27 (1.0) 0.26 (0.87)c
Female infant 229 (47.8%) 484 (48.4%)
a34 missing data on maternal anxiety and 77 missing data on maternal depression in Project Viva
b86 missing data on maternal depression and anxiety in the Generation R Study
c1 missing data for birthweight-for-gestational age in Generation R Study
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magnitude of the effect. Using a blood and brain DNA
methylation reference database, we observed moderate
correlations among three brain regions with blood cells at
the discovered and validated CpG site in the ZNF575 gene.
The Zinc Finger Protein 575 gene (ZNF575) is part of
a large family of zinc finger proteins with multiple
diverse functions that are abundant across multiple
eukaryotic genomes [18]. This protein is involved in
transcriptional regulation and has been previously asso-
ciated with lung cancer [19]. Otherwise, there is very
little known about the function of the ZNF575 gene and
its role in health or development. This top finding was
persistent in early, at approximately 3 years of age, but
not in mid-childhood in the discovery cohort. This is
important, as the first 1000 days of life represent a
period of rapid development and vulnerability able to
influence the life course further stressing the need to
fully characterize the function of the ZNF575 gene.
There were an additional 15 CpG sites in cord blood
associated with maternal antidepressant use that sur-
vived Bonferroni correction in Project Viva, but they
were not replicated in The Generation R Study. Six prior
studies of in utero antidepressant exposure and offspring
DNA methylation were recently systematically reviewed
by Viuff et al. [20]. The authors concluded that there
was no consistent association among studies and
highlighted the need for untargeted epigenetic assays
with external validation [20]. None of the prior studies
reported differentially methylated sites at/near ZNF575.
Three of the studies used a candidate gene approach
[21–23]; two used an earlier epigenome-wide array
which analyzed only 27,000 CpG sites [24, 25]. Only one
prior study by Non et al. examined associations between
maternal SSRI use and offspring DNA methylation using
the same DNA methylation platform as we did [26].
They used a case-control design of 22 exposed infants and
23 unexposed infants and found no significant association
between SSRIs and offspring DNA methylation. In
addition, Non and colleagues selected infants exposed to
SSRIs that differ from the medications used in our popula-
tion and did not adjust for cell-type composition. Lack of
consistency found in the literature may be a result of dif-
ferences in study design, population, technology for DNA
methylation assessment, and smaller sample sizes as well
as exposure timing and ascertainment.
A few of the cohort-specific associations of high levels
of pregnancy-related anxiety with DNA methylation in
Project Viva were consistent with prior literature. For
Table 2 Differentially methylated CpGs in umbilical cord blood DNA associated with prenatal maternal antidepressants in pregnancy
CpG Chr Genomic
Position
Gene Discovery cohort Project Viva (n = 479) Replication cohort Generation R Study
(n = 999c)
Mean (SD)
%-DNA
methylation
Adjusted % change in DNA
methylation (95% CI)a
P Mean (SD)
%-DNA
methylation
Adjusted % change in
DNA methylation
(95% CI)b
P
cg00367463 1 45,249,899 BEST4 1.9 (0.4) 0.26 (0.16, 0.37) 2.01 × 10−8 10.3 (2.7) − 0.53 (− 1.02, − 0.03) 0.04
cg27566858 1 208,084,099 CD34 2.0 (0.3) 0.27 (0.15, 0.39) 3.13 × 10−9 12.6 (3.3) 0.26 (− 0.53, 1.06) 0.52
cg03536711 1 221,509,067 LOC400804 53.3 (11.4) − 11.63 (− 15.80, −7.45) 3.24 × 10−8 54.9 (9.3) 2.25 (− 1.53, 6.02) 0.24
cg07729367 3 128,479,008 RAB7A 98.2 (0.5) − 0.49 (− 0.70, − 0.27) 1.08 × 10−7 90.6 (2.1) − 0.31 (− 1.36, 0.75) 0.57
cg22065513 3 144,241,532 97.1 (1.4) − 1.22 (− 1.73, − 0.72) 4.11 × 10−9 90.7 (2.0) − 0.36 (− 1.33, 0.61) 0.47
cg27299660 3 171,527,797 PLD1 1.7 (0.4) 0.77 (0.49, 1.04) 1.19 × 10−7 8.3 (2.3) 0.11 (− 0.55, 0.77) 0.75
cg14499053 7 19,158,954 2.2 (0.5) − 0.33 (− 0.45, − 0.22) 5.44 × 10−8 11.5 (2.1) 0.35 (− 0.48, 1.19) 0.41
cg15881597 7 73,085,754 VPS37D 40.1 (4.9) − 3.64 (− 5.09, − 2.19) 5.66 × 10−9 47.3 (4.7) − 1.82 (− 4.06, 0.42) 0.11
cg06645921 12 8,025,394 SLC2A14 6.6 (3.7) − 2.38 (− 2.95, − 1.81) 9.11 × 10−16 NA NA NA
cg27161197 12 47,224,649 71.5 (5.9) − 5.17 (− 7.12, − 3.23) 1.77 × 10−9 68.9 (5.5) − 2.01 (− 5.23, 1.21) 0.22
cg25121621 15 45,926,780 SQRDL 19.6 (2.9) 2.74 (1.82, 3.67) 2.71 × 10−12 28.4 (4.2) − 0.80 (− 4.37, 2.78) 0.66
cg06358612 17 28,619,293 BLMH 1.4 (0.3) 0.22 (0.14, 0.31) 6.07 × 10−8 8.1 (1.4) − 0.18 (− 0.71, 0.34) 0.49
cg22159528 19 44,039,727 ZNF575 51.0 (6.8) − 7.23 (− 10.36, − 4.10) 1.03 × 10−8 54.7 (5.9) − 2.46 (− 4.23, − 0.69) 0.006
cg12489353 19 48,231,499 EHD2 79.3 (14.5) − 10 (− 15.7, − 4.3) 7.88 × 10−8 77.2 (10) − 0.80 (− 6.49, 4.88) 0.78
cg11449935 20 35,202,477 TGIF2 2.2 (0.4) 0.29 (0.16, 0.43) 4.20 × 10−8 10.2 (2.2) 0.31(− 0.52, 1.13) 0.47
cg18036763 22 45,404,910 PHF21B 10.2 (3.6) 3.24 (1.75, 4.74) 7.62 × 10−8 6.2 (1.7) 0.38 (− 0.34, 1.11) 0.30
Abbreviations: SD standard deviation, CI confidence interval, NA excluded from the replication cohort (Generation R Study) after standard quality control
aAdjusted for maternal age, parity, race/ethnicity, smoking (never, former and during pregnancy), pre-pregnancy BMI, mode of delivery, education and infant sex,
gestational age, and estimated cord blood nucleated cells (CD8, CD4, Mono, NK, B cells, granulocytes and nRBCs)
bAdjusted for the same covariates as above and included sample plate as an additional covariate
cRefers to sample size for cg22159528, whereas other models from Generation R Study excluded samples that failed at specific CpG sites (smallest sample size
n = 970 for cg18036763)
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Fig. 1 Regional Manhattan plot for the adjusted association of prenatal maternal antidepressants and umbilical cord blood DNA methylation
within ZNF575 gene region in Project Viva (orange squares indicate exons; orange lines indicate introns; green squares indicate CpG islands)
Fig. 2 Unadjusted %-DNA methylation distribution for antidepressants exposed and unexposed infants at the replicated CpG site (cg22159528) in
the ZNF575 gene and unadjusted Wilcoxon-rank sum test P value in the discovery cohort, Project Viva, measured at three time points: a umbilical
cord blood (n = 479), b early childhood (n = 120), and c mid-childhood peripheral blood (n = 460). One hundred twelve participants in early childhood
also had cord blood measurements, and 235 participants from mid-childhood also had cord blood measurements
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example, a CpG site in the glial cell-derived neuro-
trophic factor (GDNF) gene showed higher DNA methy-
lation compared to low or moderate pregnancy-related
anxiety. Using blood samples, a study on inflammatory
markers of women with antenatal depression found
DNA methylation at another CpG site near GDNF to be
higher among depressed pregnant women [27]. Also, in
a mouse model, DNA methylation of the GDNF gene in
experimentally stressed mice has been shown to be dif-
ferentially methylated relative to stress. These experi-
ments also showed that chronic stress reduced levels of
a histone modification, H3K4me3, in the promoter
region of the GDNF gene and this effect was reversed by
antidepressants [28].
Our study has several limitations. In Project Viva, over
seven types of antidepressants were used during preg-
nancy with some women prescribed more than one
single type, although 12/14 were SSRIs (Additional file 1:
Table S2). In the Generation R Study, antidepressant
prescriptions were limited to tricyclic antidepressants
and SSRIs. In addition, in the Generation R Study,
general anxiety during pregnancy was ascertained while
pregnancy-related anxiety was evaluated in Project Viva.
These are different scales and could capture different
sources and levels of anxiety. Moreover, we measured
DNA methylation only in blood and it is likely that
blood may not accurately reflect DNA methylation
variability in other relevant tissues. However, we used
external brain and blood reference DNA methylation
data to compare correlations at the externally replicated
site. Our hypothesis was based on DNA methylation
programming during fetal development. However,
another possibility is that of cellular polycreodism—or
the systematic variability of cell fate to yield a distinctive
repertoire of cells [29]. Yet, without experimental data, it
is impossible to determine the true causal effects of
these exposures in the epigenome and therefore results
should be interpreted as biomarkers. It would be nearly
impossible to conduct a randomized trial for these pre-
natal maternal exposures and conditions. Additionally,
timing, severity, and accuracy of self-reported depression
and pregnancy-related anxiety along with medication
adherence for antidepressants and repeated exposure
could introduce substantial exposure misclassification
making it challenging to capture underlying associations.
Further, any study of the effects of medications can be
affected by confounding by indication. Specifically, it
may be the most depressed or anxious women who were
treated with antidepressants and that those underlying
causes were truly responsible for the observed associa-
tions. This issue is further complicated by the small
overlap of women who exhibited symptoms of anxiety
(n = 2) or depression (n = 4) among the treated women
in Project Viva. The two cohorts also differed from one
another, especially with respect to ethnicity (Table 1),
which may have limited our ability to replicate findings
across different populations. Lastly, our antidepressant-
exposed sample was small, limiting statistical power.
Our study also has important strengths. First, we
implemented an epigenome-wide approach to agnosti-
cally capture associations with a relatively large sample
size. Our prospective design reduces the chance of bias
Fig. 3 Scatterplots and correlations for cg22159528 (ZNF575 gene) methylation levels of blood DNA and four brain regions: prefrontal cortex
(PC, n = 74), entorhinal cortex (EC, n = 71), superior temporal gyrus (STG, n = 75), and cerebellum (CE, n = 71). Samples from external paired dataset
of blood and brain tissue of adults [51].
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that might arise from case-control studies and allowed
us to collect valuable confounder information early
during pregnancy. Another major strength is the replica-
tion of findings in an independent birth cohort. Our use
of an external reference dataset demonstrated moderate
to strong correlations between DNA methylation of
blood and three brain regions in the replicated site
(ZNF575), suggesting that this finding may be relevant
to long-term mental health or neurodevelopment. Yet,
more work is needed to fully characterize the function
of the ZNF575 gene.
Conclusion
In conclusion, we found DNA methylation of the
ZNF575 gene in infant cord blood to be associated with
maternal antidepressant use in pregnancy in two inde-
pendent cohorts. We also demonstrated that this associ-
ation persists into early childhood. These findings
warrant further study to confirm the association and to
determine its clinical significance.
Methods
Discovery cohort: Project Viva
We studied mother-child pairs participating in Project
Viva, a prospective pre-birth cohort study recruited
between 1999 and 2002 from Atrius Harvard Vanguard
Medical Associates in MA, USA [30]. Mothers provided
written, informed consent, and the institutional review
board of Harvard Pilgrim Health Care approved the
study. Of the total 2128 singleton births, there were 485
infants with cord blood DNA methylation data and
information on prenatal maternal antidepressants,
anxiety, and depression. We excluded 6 infants with ges-
tational age < 34 weeks and analyzed 479 mother-infant
pairs with cord blood DNA methylation. We evaluated
persistence of epigenetic associations observed at birth
in 120 children (n = 112 included in cord blood analyses)
with peripheral blood DNA methylation measurements
from early childhood (mean 3.4 years, range 2.9 to 5.3)
and 460 children (n = 235 included in cord blood
analyses) with peripheral blood DNA samples from mid-
childhood (mean 7.9 years, range 6.7 to 10.5).
We defined women as exposed to antidepressants if
the medical record included a prescription during preg-
nancy (Additional file 1: Table S2). To assess anxiety, at
the mid-pregnancy visit, we administered the 7-item
Pregnancy-Related Anxiety Scale (PRAS) [31]. Answers
are on a 4-point Likert scale (very much, moderately,
somewhat, and not at all). The scale captures worry
about fetal growth, health, and delivery method. The
PRAS specifies three categories of anxiety levels (low,
moderate, and high) with good reliability (Cronbach
alpha = 0.78) [32]. We classified mothers as having high
pregnancy-related anxiety if they chose “very much” to
three or more questions on the PRAS and all other
women served as the reference group. To assess depres-
sion at the mid-pregnancy visit, we administered the
Edinburgh Postnatal Depression Scale (EPDS) [33], a
10-item questionnaire screening for depressive symp-
toms. Answers are on a 4-point Likert scale from 0 to 3.
The EPDS is a validated screener for probable depression
but it is not intended to diagnose clinical depression. The
scale has been validated in pregnant women and has a
sensitivity of 86% and a specificity of 78% for the diagnosis
of depression [33, 34]. A score > 13 on the 0–30 scale
indicates probable prenatal depression [35, 36].
To assess DNA methylation, we used umbilical cord
blood collected at delivery and whole blood samples
from early and mid-childhood visits. Technicians
extracted DNA using the Qiagen Puregene Kit (Valencia,
CA) and stored aliquots at − 80 °C until analysis. DNA
underwent sodium bisulfite conversion using the EZ
DNA Methylation-Gold Kit (Zymo Research, Irvine,
CA). Samples were shipped to Illumina Inc. and ana-
lyzed for DNA methylation at > 485,000 CpG sites
simultaneously using the Infinium Human Methyla-
tion450 BeadChip (Illumina, San Diego, CA).
We used a two-stage algorithm in which we randomized
12 samples to each chip and then randomly assigned eight
chips to each of the 15 plates used to ensure balance by
sex across chips and plates. We excluded samples as
potentially mislabeled if they were mismatched on sex,
genotype or were deemed to be low in quality. Back-
ground correction and dye-bias equalization was per-
formed via the normal-exponential out-of-band (noob)
method [37], and a β-mixture quantile intra sample
normalization procedure (BMIQ) was applied to the data
to reduce the potential bias that can arise from probe
design [38]. For each CpG site, methylation is reported as
average β value =M/(M +U + ε), where M and U repre-
sent the average fluorescence intensity from each probe
corresponding to the methylated and unmethylated target
CpG and ε = 100, a small quantity to protect against
division by zero. Thus, the average β value is an
interval-scaled quantity between zero and one interpreted
as the fraction of DNA molecules whose target CpG is
methylated across all nucleated cells. We excluded
individual probes if they had non-significant detection
P values (P > 0.05) for more than 1% of the samples.
Additionally, non-CpG probes (probes for SNPs (rs) and
methylated sites other than cytosine (ch)), probes in X and
Y chromosomes, SNP-associated probes at either the
single base extension or within the target region were
removed for SNPs that have a minor-allele frequency
of > 5%. Any probe with a SNP < 10 base pairs was
excluded using annotation from the Bioconductor package
IlluminaHumanMethylation450kanno.ilmn12.hg19 that
utilized information from dbSNP. Previously identified
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non-specific and cross-reactive probes within the array
along with polymorphic CpG sites were also excluded
from the analysis [39]. We excluded individual probes
with values greater than three times the interquartile
range (IQR) from the 75th percentile or values less than
three times the IQR from the 25th percentile to eliminate
potential DNA methylation outliers. We used ComBat
[40] to correct for technical variability from plate and scan-
ner. We visually inspected the effectiveness of adjustment
for batch using principal components before and after
batch adjustment. We calculated the genomic inflation fac-
tor (λ) for all three EWAS to evaluate systemic biases.
After quality control, there were 372,563 loci for
analysis. We logit-transformed methylation values on the
β values (bounded between 0 and 100%) to M values
prior to analyses as previously described to be more
appropriate for the differential analysis of DNA methyla-
tion [41] but report results as %-change in DNA methy-
lation for interpretability.
Replication cohort: the Generation R Study
We pursued external replication of the top differentially
methylated sites in Project Viva in an independent birth
cohort study, the Generation R Study, based in Rotter-
dam, the Netherlands. For the Generation R Study, all
pregnant women living in Rotterdam with an expected
delivery date between April 2002 and January 2006 were
asked to participate. In total, 9778 mothers were
enrolled [42]. Cord blood DNA methylation was mea-
sured using Illumina Infinium HumanMethylation450
BeadChip (Illumina Inc., San Diego, USA).
Preparation and normalization of the HumanMethyla-
tion450 BeadChip array data were performed according
to the CPACOR workflow [43] using the software
package R [44]. In detail, the idat files were read using
the minfi package. Probes that had a detection P value
above background (based on the sum of methylated and
unmethylated intensity values) ≥ 1 × 10−16 were set to
missing per array. Next, the intensity values were strati-
fied by autosomal and non-autosomal probes and quan-
tile normalized for each of the six probe type categories
separately: type II red/green, type I methylated red/
green, and type I unmethylated red/green. Beta values
were calculated as the proportion of methylated intensity
value on the sum of methylated + unmethylated + 100
intensities. Arrays with observed technical problems
such as failed bisulfite conversion, hybridization or
extension, and arrays with a mismatch between sex of
the proband and sex determined by the chr X and Y
probe intensities were removed from subsequent ana-
lyses. Additionally, only arrays with a call rate > 95% per
sample were processed further.
A subset of N = 999 mother-child pairs had
complete information on maternal antidepressant use
in pregnancy, and N = 969 had complete information
on maternal depression and anxiety. Maternal pre-
natal depression and anxiety were assessed at 20
weeks of pregnancy with the Brief Symptom Inven-
tory [45, 46]. This questionnaire comprises 53 items
which provided nine scales of various psychiatric
symptoms. The scale has a global index and includes
two subscales for anxiety and depressive symptoms.
The subscales for anxiety and depression contained
six items each on a 5-point scale, from 0 to 4 where
a higher score indicates a higher level of symptoms.
Antidepressant use was reported during each trimester of
pregnancy using a self-reported questionnaire. Use of SSRI
was confirmed with prescription records from pharmacies
with participant consent. These measurements have been
previously described in detail [42, 47, 48].
Statistical analyses
For each covariate in both discovery and replication
cohorts, we calculated means and standard deviations
(SD), or sample sizes and percentages, to describe the
discovery and replication cohorts. In the discovery
cohort, we performed epigenome-wide DNA methyla-
tion analyses on a CpG-by-CpG basis to assess DNA
methylation differences at each site in cord blood rela-
tive to prenatal maternal exposure to (1) antidepressant
prescription, (2) anxiety, and (3) depression compared to
non-exposed infants. We used separate robust linear
regression models with heteroskedasticity-consistent
estimators to model the methylation levels of each indi-
vidual CpG on the M value scale as the dependent
variable and antidepressants, high pregnancy-related
anxiety, and depression as predictors. We adjusted all
regression models for variables selected a priori:
maternal age, parity, self-reported race, smoking
during pregnancy, body mass index (BMI), mode of
delivery, education and infant sex, gestational age at birth,
and nucleated cell-type proportions in cord blood (CD8+
T cells, CD4+ T cells, monocytes, natural killer cells, B
cells, granulocytes, and nucleated red blood cells for cord
blood analyses) estimated from the DNAm data using
minfi [49]. Statistical significance for the CpG-by-CpG
analyses was adjusted by controlling the false discovery
rate at 5% (FDR < 0.05) for each of the three-independent
epigenome-wide analyses. As secondary analyses, we
tested for differentially methylated regions in relationship
to antidepressant prescription, anxiety, and depression
using DMRcate [50] with an FDR < 0.05.
Similarly, in the replication cohort, we fit a robust
linear regression with each of the top CpGs from
discovery as the outcome for each prenatal maternal
exposure and adjusted for similar covariates as we
had in discovery. We tested CpG sites associated with
prenatal maternal antidepressant use that passed
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Bonferroni correction in the discovery cohort due to an
early departure from the expected uniform distribution
for this EWAS (Additional file 2: Figures S1-S2) and for
depression and anxiety among significant differentially
methylated sites that passed FDR < 0.05. In replication
analyses, we deemed a P < 0.05 as statistically significant
in addition to having the association be consistent in
direction with the discovery cohort.
We also evaluated the persistence of associations in
early and mid-childhood in Project Viva by carrying for-
ward individual loci found to be associated with DNA
methylation in cord blood analyses that also replicated in
the Generation R Study. Persistence of DNA methylation
differences was evaluated in peripheral blood samples
collected during early and mid-childhood using
multivariate robust linear regression models adjusting for
the same covariates as cord blood models with the
addition of child age at the time of the blood draw. We
considered P < 0.05 as statistically significant for the
persistence of epigenetic alterations in early or mid-child-
hood peripheral blood analyses. We also investigated un-
adjusted DNA methylation differences between exposed
and unexposed children using boxplots and a
Wilcoxon-rank sum test. We present the unadjusted dis-
tribution of DNA methylation levels in boxplots by anti-
depressant prescription given the relative small number of
exposed infants. All analyses were carried out using the R
statistical package, version 3.4.1 (www.r-project.org/).
Blood-brain DNA methylation samples
We evaluated co-variation between blood DNA methyla-
tion and methylation levels of brain regions using publicly
available data from the Gene Expression Omnibus (GEO)
repository (GSE59685). Briefly, to generate reference data,
investigators collected whole blood samples prior to death
and matched those samples to postmortem samples from
the prefrontal cortex, entorhinal cortex, superior temporal
gyrus and cerebellum of N = 75 men and women (40–105
years old) [51]. They measured DNA methylation using the
Illumina HumanMethylation450 BeadChip Array. Scatter
plots and person correlation coefficients for the relationship
between blood and brain DNA methylation was examined
among sites that replicated in the external cohort.
Additional files
Additional file 1: Table S1. Differentially methylated CpG sites in umbilical
cord blood DNA associated with high anxiety and depression (FDR < 0.05 for
the discovery cohort, Project Viva) and replication results from the Generation
R Study. Table S2. Type of prenatal maternal antidepressants prescribed to
the 14 unique participants in Project Viva. (DOCX 19 kb)
Additional file 2: Figure S1. Quantile-Quantile plots of observed vs
expected P values and genomic inflation factor (λ) for Epigenome-Wide
Associations of prenatal maternal A) prenatal antidepressants B) high
pregnancy-related anxiety and C) depression. Figure S2. Manhattan plots
for Epigenome-Wide Associations of prenatal maternal A) antidepressants
B) high pregnancy-related anxiety and C) depression. (DOCX 852 kb)
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